Canopy Growth (NYSE:CGC) and Nutra Pharma (OTCMKTS:NPHC) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Institutional & Insider Ownership

12.8% of Canopy Growth shares are held by institutional investors. Comparatively, 0.0% of Nutra Pharma shares are held by institutional investors. 61.5% of Nutra Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings for Canopy Growth and Nutra Pharma, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Canopy Growth 0 1 4 0 2.80
Nutra Pharma 0 0 0 0 N/A

Canopy Growth presently has a consensus price target of $60.50, indicating a potential upside of 38.00%. Given Canopy Growth’s higher possible upside, equities analysts clearly believe Canopy Growth is more favorable than Nutra Pharma.

Valuation and Earnings

This table compares Canopy Growth and Nutra Pharma’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Canopy Growth $60.79 million 167.43 -$54.88 million ($0.32) -137.00
Nutra Pharma $120,000.00 5.00 -$4.02 million N/A N/A

Nutra Pharma has lower revenue, but higher earnings than Canopy Growth.

Risk & Volatility

Canopy Growth has a beta of 4.46, suggesting that its share price is 346% more volatile than the S&P 500. Comparatively, Nutra Pharma has a beta of 6.11, suggesting that its share price is 511% more volatile than the S&P 500.

Profitability

This table compares Canopy Growth and Nutra Pharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Canopy Growth -503.14% -26.32% -18.43%
Nutra Pharma -4,741.67% N/A -1,740.23%

Summary

Canopy Growth beats Nutra Pharma on 7 of the 11 factors compared between the two stocks.

Canopy Growth Company Profile

Canopy Growth Corporation, together with its subsidiaries, engages in growing, possession, and sale of medical cannabis in Canada. Its products include dried flowers, oils and concentrates, softgel capsules, and hemps. The company offers its products under the Tweed, Black Label, Spectrum Cannabis, DNA Genetics, Leafs By Snoop, Bedrocan Canada, CraftGrow, and Foria brand names. It also offers its products through Tweed Main Street, a single online platform that enables registered patients to purchase medicinal cannabis from various producers across various brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.

Nutra Pharma Company Profile

Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States. The company offers Nyloxin and Nyloxin Extra Strength products, which are used as an oral spray for treating back pain, neck pain, headaches, joint pain, migraines, and neuralgia, as well as a topical gel for treating joint pain, neck pain, arthritis pain, and pain associated with repetitive stress; Pet Pain-Away, an over-the-counter pain reliever to treat pain in cats and dogs; Luxury Feet, an over-the-counter pain reliever to treat foot pain from high heels and stilettos; Nyloxin Military Strength for treating pain to the United States Military and Veteran's Administration; and Equine Nyloxin, a topical therapy for chronic pain in horses. It is also developing RPI-78M to treat neurological diseases and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases, including human immunodeficiency virus/AIDS and herpes; RPI-78 for pain and arthritis; and RPI-70 for pain. The company has a collaboration agreement with the International Security Group to develop nerve agent counter measures. Nutra Pharma Corp. was founded in 2000 and is based in Coral Springs, Florida.

Receive News & Ratings for Canopy Growth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Canopy Growth and related companies with MarketBeat.com's FREE daily email newsletter.